中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 8
Aug.  2017
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2017  >  33(8): 1589-1594

Pharmacotherapy for primary biliary cholangitis: basic concepts and research advances

DOI: 10.3969/j.issn.1001-5256.2017.08.039

  • Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai Institute of Liver diseases

  • Received Date: 2017-02-21
  • Published Date: 2017-08-20
    Abstract
  • Primary biliary cholangitis ( PBC) is a chronic progressive cholestatic liver disease of unknown etiology characterized by highly specific anti-mitochondrial antibody in serum and immune-mediated non-pyogenic destructive infection in the small intrahepatic bile ducts, which can lead to portal inflammation and fibrosis and finally progress to liver cirrhosis and liver failure. At present, ursodeoxycholic acid ( UDCA) is the only drug approved for the treatment of PBC with a recommended dose of 13-15 mg·kg-1·d-1. There are significant improvements in the survival rate of patients achieving biochemical response after UDCA treatment. However, about 40% of PBC patients do not respond to UDCA, and such patients have a risk of disease progression and are in urgent need of other drugs. With reference to recent clinical studies and guidelines, this article summarizes the basic concepts and latest advances in pharmacotherapy for PBC, as well as the perspectives of new drugs in clinical trials, in order to bring new hopes to PBC patients with poor response to UDCA.

     

    • FullText(HTML)
  • loading
    • References(42)
  • [1]CAREY EJ, ALI AH, LINDOR KD.Primary biliary cirrhosis[J].Lancet, 2015, 386 (10003) :1565-1575.
    [2]CZUL F, LEVY C.Novel therapies on primary biliary cirrhosis[J].Clin Liver Dis, 2016, 20 (1) :113-130.
    [3]DYSON JK, HIRSCHFIELD GM, ADAMS DH, et al.Novel therapeutic targets in primary biliary cirrhosis[J].Nat Rev Gastroenterol Hepatol, 2015, 12 (3) :147-158.
    [4]WANG L, GERSHWIN ME, WANG FS.Primary biliary cholangitis in China[J].Curr Opin Gastroenterol, 2016, 32 (3) :195-203.
    [5]MAYO MJ.Natural history of primary biliary cirrhosis[J].Clin Liver Dis, 2008, 12 (2) :277-288.
    [6]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of cholestatic liver diseases[J].J Hepatol, 2009, 51 (2) :237-267.
    [7]TRIVEDI PJ, CORPECHOT C, PARES A, et al.Risk stratification in autoimmune cholestatic liver diseases:opportunities for clinicians and trialists[J].Hepatology, 2016, 63 (2) :644-659.
    [8]de VRIES E, BEUERS U.Management of cholestatic disease in2017[J].Liver Int, 2017, 37 (Suppl 1) :123-129.
    [9]POUPON R.Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases:an overview of their mechanisms of action[J].Clin Res Hepatol Gastroenterol, 2012, 36 (Suppl 1) :s3-s12.
    [10]BEUERS U, TRAUNER M, JANSEN P, et al.New paradigms in the treatment of hepatic cholestasis:from UDCA to FXR, PXR and beyond[J].J Hepatol, 2015, 62 (1 Suppl) :s25-s37.
    [11]GOULIS J, LEANDRO G, BURROUGHS AK.Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis:a meta-analysis[J].Lancet, 1999, 354 (9184) :1053-1060.
    [12]POUPON RE, BALKAU B, ESCHWGE E, et al.A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis.UDCA-PBC Study Group[J].N Engl J Med, 1991, 324 (22) :1548-1554.
    [13]HUET PM, VINCENT C, DESLAURIER J, et al.Portal hypertension and primary biliary cirrhosis:effect of long-term ursodeoxycholic acid treatment[J].Gastroenterology, 2008, 135 (5) :1552-1560.
    [14]BATTS KP, JORGENSEN RA, DICKSON ER, et al.Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis[J].Am J Gastroenterol, 1996, 91 (11) :2314-2317.
    [15]COMBES B, CARITHERS RL Jr, MADDREY WC, et al.A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis[J].Hepatology, 1995, 22 (3) :759-766.
    [16]POUPON RE, LINDOR KD, PARS A, et al.Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis[J].J Hepatol, 2003, 39 (1) :12-16.
    [17]KUIPER EM, HANSEN BE, de VRIES RA, et al.Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid[J].Gastroenterology, 2009, 136 (4) :1281-1287.
    [18]ter BORG PC, SCHALM SW, HANSEN BE, et al.Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis.Results of a 10-yr cohort study involving 297 patients[J].Am J Gastroenterol, 2006, 101 (9) :2044-2050.
    [19]PARS A, CABALLERA L, RODS J.Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid[J].Gastroenterology.2006, 130 (3) :715-720.
    [20]CORPECHOT C, ABENAVOLI L, RABAHI N, et al.Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J].Hepatology, 2008, 48 (3) :871-877.
    [21]CORPECHOT C, CHAZOUILLRES O, POUPON R.Early primary biliary cirrhosis:biochemical response to treatment and prediction of long-term outcome[J].J Hepatol, 2011, 55 (6) :1361-1367.
    [22]ANGULO P, DICKSON ER, THERNEAU TM, et al.Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis:a randomized trial[J].J Hepatol, 1999, 30 (5) :830-835.
    [23]KUMAGI T, GUINDI M, FISCHER SE, et al.Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis[J].Am J Gastroenterol, 2010, 105 (10) :2186-2194.
    [24]AZEMOTO N, KUMAGI T, ABE M, et al.Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis[J].Hepatol Res, 2011, 41 (4) :310-317.
    [25]ANGULO P, LINDOR KD, THERNEAU TM, et al.Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid[J].Liver, 1999, 19 (2) :115-121.
    [26]LAMMERS WJ, van BUUREN HR, HIRSCHFIELD GM, et al.Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis:an international follow-up study[J].Gastroenterology, 2014, 147 (6) :1338-1349.
    [27]LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology, 2015, 149 (7) :1804-1812.
    [28]GONG Y, HUANG Z, CHRISTENSEN E, et al.Ursodeoxycholic acid for patients with primary biliary cirrhosis:an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses[J].Am J Gastroenterol, 2007, 102 (8) :1799-1807.
    [29]CARBONE M, MELLS GF, PELLS G, et al.Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J].Gastroenterology, 2013, 144 (3) :560-569.
    [30]HIRSCHFIELD GM, MASON A, LUKETIC V, et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology, 2015, 148 (4) :751-761.
    [31]NEVENS F, ANDREONE P, MAZZELLA G, et al.A placebocontrolled trial of obeticholic acid in primary biliary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.
    [32]TANAKA A, HIROHARA J, NAKANUMA Y, et al.Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA[J].J Gastroenterol, 2015, 50 (6) :675-682.
    [33]HOSONUMA K, SATO K, YAMAZAKI Y, et al.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J].Am J Gastroenterol, 2015, 110 (3) :423-431.
    [34]HAZZAN R, TUR-KASPA R.Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid[J].J Clin Gastroenterol, 2010, 44 (5) :371-373.
    [35]RUDIC JS, POROPAT G, KRSTIC MN, et al.Bezafibrate for primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2012, 1:CD009145.
    [36]WALKER LJ, NEWTON J, JONES DE, et al.Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J].Hepatology, 2009, 49 (1) :337-338.
    [37]CHEUNG AC, LAPOINTE-SHAW L, KOWGIER M, et al.Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes[J].Aliment Pharmacol Ther, 2016, 43 (2) :283-293.
    [38]GONG Y, GLUUD C.Colchicine for primary biliary cirrhosis:a Cochrane Hepato-Biliary Group systematic review of randomized clinical trials[J].Am J Gastroenterol, 2005, 100 (8) :1876-1885.
    [39]MYERS RP, SWAIN MG, LEE SS, et al.B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J].Am J Gastroenterol, 2013, 108 (6) :933-941.
    [40]MOUSA HS, CARBONE M, MALINVERNO F, et al.Novel therapeutics for primary biliary cholangitis:toward a disease-stagebased approach[J].Autoimmun Rev, 2016, 15 (9) :870-876.
    [41]ADAM R, KARAM V, DELVART V, et al.Evolution of indications and results of liver transplantation in Europe.A report from the European Liver Transplant Registry (ELTR) [J].J Hepatol, 2012, 57 (3) :675-688.
    [42]BOSCH A, DUMORTIER J, MAUCORT-BOULCH D, et al.Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence[J].J Hepatol, 2015, 63 (6) :1449-1458.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1691) PDF downloads(391) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return